Skip to main content
3227 search results for:

Natalizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Natalizumab | News

    Natalizumab

    Pulmonary embolism and cerebral venous thrombosis
  2. 29-04-2024 | Natalizumab | ReviewPaper

    PB006: A Natalizumab Biosimilar

    PB006 (Tyruko®) is the first biosimilar of the reference monoclonal anti-α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults …

  3. 01-04-2024 | Ocrelizumab | News

    AZD-1222/Natalizumab/Ocrelizumab

    Brachial and lumbosacral plexitis and lack of efficacy
  4. Open Access 01-12-2024 | Natalizumab | OriginalPaper

    Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report

    Natalizumab is a monoclonal antibody used to treat patients with relapsing–remitting multiple sclerosis (RRMS). The antibody selectively binds and inhibits the α4 subunit of the α4β1-integrin, very late antigen-4 (VLA-4), blocking interaction with …

  5. 01-04-2024 | Natalizumab | News

    Natalizumab

    Progressive multifocal leukoencephalopathy
  6. 01-03-2024 | Natalizumab | News

    Natalizumab

    Various toxicities
  7. 29-02-2024 | Natalizumab | OriginalPaper

    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study

    Conversion to secondary progression (SP) in relapse-onset multiple sclerosis (RoMS) is one of the most striking events during the disease course. It occurs in 50–80% of patients with untreated RoMS after two decades [ 1 ], and inaugurates a period …

  8. 01-02-2024 | Natalizumab | News

    Natalizumab

    CNS varicella zoster vasculitis and acute retinal necrosis
  9. Open Access 04-03-2024 | Natalizumab | BriefCommunication

    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials

    This study explored the effects of ocrelizumab, a monoclonal antibody targeting CD20-positive B cells, on the immune system of MS patients. Using CyTOF technology, researchers extensively analysed immune cell subsets in patients undergoing …

  10. Open Access 08-03-2024 | Natalizumab | ReviewPaper

    Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis

    Multiple sclerosis [MS] is a chronic inflammatory neurological immune-mediated disease of the central nervous system [CNS] arising from the interaction of genetic and environmental factors. It is characterized by inflammatory demyelination of the …

  11. 01-02-2024 | Natalizumab | News

    Drug-induced PML greatest with natalizumab for MS

  12. 01-01-2024 | Multiple Sclerosis | News

    Natalizumab

    Paradoxical tumefactive worsening of multiple sclerosis and lack of efficacy
  13. 01-12-2023 | Natalizumab | News

    Natalizumab

    Progressive multifocal leukoencephalopathy
  14. 01-12-2023 | Ocrelizumab | News

    Natalizumab/Ocrelizumab

    Lack of efficacy
  15. 01-11-2023 | Natalizumab | News

    Natalizumab

    Lack of efficacy: 2 case reports
  16. Open Access 20-09-2023 | Natalizumab | OriginalPaper

    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study

    Natalizumab (NAT, Biogen Idec Inc, Cambridge, Massachusetts, USA) is a monoclonal antibody that was approved in 2004 for the treatment of active relapsing–remitting multiple sclerosis (MS) [ 1 ]. NAT blocks the alpha4-beta1 integrin receptor on …

  17. Open Access 16-09-2023 | Natalizumab | OriginalPaper

    Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

    Multiple sclerosis (MS) is an inflammatory disorder affecting the central nervous system and causing several clinical deficits. It is the most common neurological cause of disability in young adults [ 1 ]. The most recent analyses from the World …

  18. Open Access 01-12-2023 | Multiple Sclerosis | OriginalPaper

    High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro

    Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) affecting more than 2.8 million people worldwide [ 1 , 2 ]. The major pathological hallmarks of MS are blood–brain barrier (BBB) breakdown, immune cell …

  19. Open Access 16-09-2023 | Natalizumab | OriginalPaper

    Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells

    Migration of lymphocytes into the central nervous system (CNS) is an essential process in the pathogenesis of the inflammatory demyelinating disease, multiple sclerosis (MS) [ 1 ].

  20. 01-10-2022 | Multiple Sclerosis | OriginalPaper

    Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab

    Natalizumab (NTZ) is a humanized monoclonal antibody directed against α4 integrin (very late antigen 4) on the surface of human lymphocytes, which interacts with the vascular cell adhesion molecule 1 expressed on vascular endothelial cells and …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.